ميمپارا

Country: Իսրայել

language: արաբերեն

source: Ministry of Health

active_ingredient:

CINACALCET HYDROCHLORIDE 60 MG

MAH:

AMGEN EUROPE B.V.

ATC_code:

H05BX01

pharmaceutical_form:

FILM COATED TABLETS

administration_route:

PER OS

manufactured_by:

AMGEN EUROPE B.V., NETHERLANDS

therapeutic_group:

CINACALCET

therapeutic_indication:

Treatment of secondary hyperparathyrodism (HPT) in patients with end-dtage renal disease (ESRD) on maintenance dialysis therapy. Mimpara may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols, as appropriate. Reduction of hypercalcaemia in patients with parathyroid carcinoma.

authorization_date:

2012-10-01